Mon, October 1, 2012
Sun, September 30, 2012
Sat, September 29, 2012
Fri, September 28, 2012
[ Fri, Sep 28th 2012 ]: Market Wire
call for signatures
Thu, September 27, 2012
[ Thu, Sep 27th 2012 ]: Market Wire
30 a.m. Eastern
Wed, September 26, 2012
Tue, September 25, 2012
Mon, September 24, 2012
Sun, September 23, 2012
Fri, September 21, 2012
Thu, September 20, 2012
Wed, September 19, 2012
Tue, September 18, 2012
Mon, September 17, 2012
[ Mon, Sep 17th 2012 ]: Market Wire
Imaging3 Files Chapter 11

Uroplasty To Participate In The Craig-Hallum Alpha Select Conference

  Copy link into your clipboard //health-fitness.news-articles.net/content/2012/ .. in-the-craig-hallum-alpha-select-conference.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

Uroplasty To Participate In The Craig-Hallum Alpha Select Conference -- MINNEAPOLIS, Sept. 25, 2012 /PRNewswire/ --

Uroplasty To Participate In The Craig-Hallum Alpha Select Conference

[ ]

MINNEAPOLIS, Sept. 25, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: [ UPI ]), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced its participation in the Craig-Hallum Alpha Select Conference on Thursday, September 27, 2012. David Kaysen, President and CEO, and Medi Jiwani, Chief Financial Officer, will present and meet with investors one on one at the conference in New York City.

Attendance at the conference is by invitation only. The presentation and the meetings will not be webcast.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at [ www.uroplasty.com ].

For Further Information:


Uroplasty, Inc.

EVC Group

David Kaysen, President and CEO, or

Doug Sherk/Jenifer Kirtland (Investors), 415.568.9349

Medi Jiwani, Vice President, CFO, Treasurer

Chris Gale (Media), 646.201.5431

952.426.6140


SOURCE Uroplasty, Inc.



[ Back to top ]

RELATED LINKS
[ http://www.uroplasty.com ]